Maria Terradas-Terradas

Maria Terradas-Terradas

Auto-generated profile, based on publicly available information

Maria Terradas-Terradas

Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1BD, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NRNeil A. Robertson
Neil A. Robertson
ELEric Latorre-Crespo
Eric Latorre-Crespo
MTMaria Terradas-Terradas
Maria Terradas-Terradas
JLJorge Lemos-Portela
Jorge Lemos-Portela
APAlison C. Purcell
Alison C. Purcell
TCTamir Chandra
Tamir Chandra
Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells carrying no or only neutral mutations. If mutations in different genes lead to distinct fitness advantages, this could enable patient stratification. We quantified the fitness effects of mutations over 12 years in older age using longitudinal sequencing and developed a filtering method that considers individual mutational context alongside mutation co-occurrence to quantify the growth potential of variants within individuals. We found that gene-specific fitness differences can outweigh inter-individual variation and, therefore, could form the basis for personalized clinical management.

13 November 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CKChristos Kiourtis
Christos Kiourtis
MTMaria Terradas-Terradas
Maria Terradas-Terradas
LGLucy M. Gee
Lucy M. Gee
SMStephanie May
Stephanie May
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
TBThomas G. Bird
Thomas G. Bird
Cellular senescence is not only associated with ageing but also impacts physiological and pathological processes, such as embryonic development and wound healing. Factors secreted by senescent cells affect their microenvironment and can induce spreading of senescence locally. Acute severe liver disease is associated with hepatocyte senescence and frequently progresses to multi-organ failure. Why the latter occurs is poorly understood. Here we demonstrate senescence development in extrahepatic organs and associated organ dysfunction in response to liver senescence using liver injury models and genetic models of hepatocyte-specific senescence. In patients with severe acute liver failure, we show that the extent of hepatocellular senescence predicts disease outcome, the need for liver transplantation and the occurrence of extrahepatic organ failure. We identify the TGFβ pathway as a critical mediator of systemic spread of senescence and demonstrate that TGFβ inhibition in vivo blocks senescence transmission to other organs, preventing liver senescence induced renal dysfunction. Our results highlight the systemic consequences of organ-specific senescence, which, independent of ageing, contributes to multi-organ dysfunction.

11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAnne-Louise Latif
Anne-Louise Latif
ANAshley Newcombe
Ashley Newcombe
SLSha Li
Sha Li
KGKathryn Gilroy
Kathryn Gilroy
NRNeil A. Robertson
Neil A. Robertson
PAPeter D. Adams
Peter D. Adams
Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BETi), targeting the BET-family co-activator BRD4, both show encouraging pre-clinical activity, but limited clinical activity as single agents. Here, we report enhanced toxicity of combined MDM2i and BETi towards AML cell lines, primary human blasts and mouse models, resulting from BETi’s ability to evict an unexpected repressive form of BRD4 from p53 target genes, and hence potentiate MDM2i-induced p53 activation. These results indicate that wild-type TP53 and a transcriptional repressor function of BRD4 together represent a potential broad-spectrum synthetic therapeutic vulnerability for AML.

1 August 2019 in Current Biology
Verified
Journal Article
Open access
NRNeil A. Robertson
Neil A. Robertson
RHRobert F. Hillary
Robert F. Hillary
DMDaniel L. McCartney
Daniel L. McCartney
MTMaria Terradas-Terradas
Maria Terradas-Terradas
JHJonathan Higham
Jonathan Higham
TCTamir Chandra
Tamir Chandra
Age-related clonal haemopoiesis (ARCH) in healthy individuals was initially observed through an increased skewing in X-chromosome inactivation [1]. More recently, several groups reported that ARCH is driven by somatic mutations [2], with the most prevalent ARCH mutations being in the DNMT3A and TET2 genes, previously described as drivers of myeloid malignancies. ARCH is associated with an increased risk for haematological cancers [2]. ARCH also confers an increased risk for non-haematological diseases, such as cardiovascular disease, atherosclerosis, and chronic ischemic heart failure, for which age is a main risk factor [3,4]. Whether ARCH is linked to accelerated ageing has remained unexplored. The most accurate and commonly used tools to measure age acceleration are epigenetic clocks: they are based on age-related methylation differences at specific CpG sites [5]. Deviations from chronological age towards an increased epigenetic age have been associated with increased risk of earlier mortality and age-related morbidities [5,6]. Here we present evidence of accelerated epigenetic age in individuals with ARCH.

28 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
NRNeil A. Robertson
Neil A. Robertson
ELEric Latorre-Crespo
Eric Latorre-Crespo
MTMaria Terradas-Terradas
Maria Terradas-Terradas
APAlison C. Purcell
Alison C. Purcell
BLBenjamin J Livesey
Benjamin J Livesey
TCTamir Chandra
Tamir Chandra
The prevalence of clonal haematopoiesis of indeterminate potential (CHIP) in healthy individuals increases rapidly from age 60 onwards and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in stem cells that are also drivers of myeloid malignancies. Since mutations in stem cells often drive leukaemia, we hypothesised that stem cell fitness substantially contributes to transformation from CHIP to leukaemia. Stem cell fitness is defined as the proliferative advantage over cells carrying no or only neutral mutations. It is currently unknown whether mutations in different CHIP genes lead to distinct fitness advantages that could form the basis for patient stratification. We set out to quantify the fitness effects of CHIP drivers over a 12 year timespan in older age, using longitudinal error-corrected sequencing data. We developed a new method based on drift-induced fluctuation (DIF) filtering to extract fitness effects from longitudinal data, and thus quantify the growth potential of variants within each individual. Our approach discriminates naturally drifting populations of cells and faster growing clones, while taking into account individual mutational context. We show that gene-specific fitness differences can outweigh inter-individual variation and therefore could form the basis for personalised clinical management.